Table 1.
Baseline characteristics of the University of California, San Francisco rheumatoid arthritis cohort*
| Characteristics | All subjects (n = 466) | PHQ-9 score <10 (n = 294) | PHQ-9 score ≥10 (n = 172) | P† |
|---|---|---|---|---|
| Women | 396 (85) | 250 (85) | 146 (85) | 0.87 |
| Age, mean ± SD years | 54.0 ± 14.0 | 54.0 ± 14.0 | 54.0 ± 14.0 | 0.57 |
| Race/ethnicity | 0.01 | |||
| Latino/Hispanic | 158 (34) | 91 (31) | 67 (39) | |
| African American | 47 (10) | 26 (9) | 21 (12) | |
| Asian/Pacific Islander | 117 (25) | 73 (25) | 43 (25) | |
| White | 144 (31) | 103 (35) | 41 (24) | |
| Hospital clinic site | 0.03 | |||
| Public | 243 (52) | 147 (50) | 100 (58) | |
| University | 223 (48) | 147 (50) | 72 (42) | |
| Disease duration, mean ± SD years | 11.0 ± 9.0 | 11.0 ± 10.0 | 11.0 ± 9.0 | 0.96 |
| HAQ score, mean ± SD | 1.2 ± 0.83 | 1.1 ± 0.74 | 1.4 ± 0.93 | <0.0001 |
| Antibody positive | ||||
| Rheumatoid factor | 364 (78) | 232 (79) | 132 (77) | 0.63 |
| Anti-CCP | 373 (80) | 235 (80) | 138 (80) | 0.93 |
| Prednisone | 292 (63) | 185 (63) | 107 (62) | 0.85 |
| Prednisone dose, mean ± SD mg | 6.0 ± 4.0 | 6.0 ± 4.0 | 7.0 ± 4.0 | 0.44 |
| DMARDs‡ | 356 (76) | 232 (79) | 124 (72) | 0.02 |
| Anti-TNFα | 122 (26) | 76 (26) | 46 (27) | 0.90 |
*
Values are the number (percentage) unless otherwise indicated. PHQ-9 = Patient Health Questionnaire 9; HAQ = Health Assessment Questionnaire; anti-CCP = anti– cyclic citrullinated peptide; DMARD = disease-modifying antirheumatic drug; anti-TNFα = anti–tumor necrosis factor α.
†
By 2-sided t-tests or Pearson’s chi-square tests, as appropriate.
‡
Includes any DMARD other than prednisone (i.e., methotrexate, hydroxychloroquine, sulfasalazine, azathioprine, leflunomide, anti-TNFα medications, and rituximab).